Table 3. Treatment regimens of trials included for analysis.
| StudyID | Treatment regimens (each 21-day cycle) | |
|---|---|---|
| ACT group | CT group | |
| Allen et al.2014 | Ziv-aflibercept 6 mg/kg on day 1+ topotecan 4 mg/m2 on days 1, 8 and 15 | topotecan 4 mg/m2 on days 1, 8 and 15 |
| Spigel et al.2011 | Bevacizumab 15 mg/kg on day 1 + etoposide 100 mg/m2 on days 1-3 + cisplatin 75 mg/m2 or carboplatin AUC = 5 mg/mL/min on day 1 | placebo 15 mg/kg on day 1+ etoposide 100 mg/m2 on days 1-3 + cisplatin 75 mg/m2 or carboplatin AUC = 5 mg/mL/min on day 1 |
| Pujol et al.2015 | Bevacizumab 7.5 mg/kg on day 1 + PS 0-1: 4'-epidoxorubicin 30 mg/m2; on day 1 + cisplatin 75 mg/m2; on day 2+ etoposide 75 mg/m2; on days 1-3 + cyclophosphamide 300 mg/m2; on days 1-3/ PS 2: cisplatin 80 mg/m2; on day 2 + etoposide 120 mg/m2; on days 1-3 | PS 0-1: 4'-epidoxorubicin 30 mg/m2; on day 1 + cisplatin 75 mg/m2; on day 2+ etoposide 75 mg/m2; on days 1-3 + cyclophosphamide 300 mg/m2; on days 1-3/ PS 2: cisplatin 80 mg/m2; on day 2 + etoposide 120 mg/m2; on days 1-3 |
| Lu et al.2015 | rh-Endostatin 7.5 mg/m2 on days 1-14 + etoposide 60 mg/m2 on days 1-5 + carboplatin AUC = 5 mg/ml/min on day 1 | etoposide 60 mg/m2 on days 1-5 + carboplatin AUC = 5 mg/ml/min on day 1 |
| Luo et al.2013 | rh-Endostatin 15 mg on days 1-14 + etoposide 100 mg on days 1-5 + carboplatin 400-500 mg on day 1 | etoposide 100 mg on days 1-5 + carboplatin 400-500 mg on day 1 |
| Dai et al.2012 | rh-Endostatin 15 mg on days 1-14 + etoposide 100 mg/m2 on days 1-5 + cisplatin 20 mg/m2; on days 2-5 | etoposide 100 mg/m2 on days 1-5 + cisplatin 20 mg/m2; on days 2-5 |
| Li et al.2010 | rh-Endostatin 15 mg on days 1-14 + etoposide 100 mg/m2 on days 1-5 + cisplatin 80 mg/m2; on day 2 | etoposide 100 mg/m2 on days 1-5 + cisplatin 80 mg/m2; on day 2 |
| Wang et al.2011 | rh-Endostatin 15 mg on days 1-14 + etoposide 100 mg on days 1-5 + cisplatin 20 mg on days 2-5 | etoposide 100 mg on days 1-5 + cisplatin 20 mg on days 2-5 |
| Hu et al.2011 | rh-Endostatin 15 mg on days 1-14 + topotecan 0.75-1.00 mg/m2 on days 1-5 + cisplatin 25 mg/m2; on days 1-3 | topotecan 0.75-1.00 mg/m2 on days 1-5 + cisplatin 25 mg/m2; on days 1-3 |
| Liu et al.2011 | Thalidomide 100 mg/d daily + etoposide 100 mg/m2; on days 1-3 + cisplatin 30 mg/m2; on days 1-3 | etoposide 100 mg/m2; on days 1-3 + cisplatin 30 mg/m2; on days 1-3 |
| Cheng et al.2015 | Thalidomide 150 mg/d daily + cisplatin 25 mg/m2 on days 1-3 + irinotecan 125 mg/m2 on days 1, 8 | cisplatin 25 mg/m2 on days 1-3 + irinotecan 125 mg/m2 on days 1, 8 |
| Liu et al.2015 | Thalidomide 100 mg/d daily + etoposide 100 mg/m2; on days 1-3 + cisplatin 30 mg/m2; on days 1-3 | etoposide 100 mg/m2; on days 1-3 + cisplatin 30 mg/m2; on days 1-3 |
| Liu et al.2013 | Thalidomide 100 mg/d daily + cisplatin 25 mg/m2 on days 1-3 + irinotecan 60 mg/m2 on days 1, 8 | cisplatin 25 mg/m2 on days 1-3 + irinotecan 60 mg/m2 on days 1, 8 |
| Pujol et al.2007 | Thalidomide 100-400 mg/d + 4'-epidoxorubicin 40 mg/m2 on day 1 + cisplatin 100 mg/m2 on day 2 + etoposide 100 mg/m2 on days 1-3+ cyclophosphamide 400 mg/m2 on days 1-3 (every 28 days) | placebo 100-400 mg/d + 4'-epidoxorubicin 40 mg/m2 on day 1 + cisplatin 100 mg/m2 on day 2 + etoposide 100 mg/m2 on days 1-3+ cyclophosphamide 400 mg/m2 on days 1-3 (every 28 days) |
| Lee et al.2009 | Thalidomide 100-200 mg/d + etoposide 120 mg/m2 on day 1 and 200 mg on days 2-3 + carboplatin AUC = 5 mg/ml/min (extensive-stage) or AUC = 6 mg/ml/min (limited-stage) on day 1 | placebo 100-200 mg/d + etoposide 120 mg/m2 on day 1 and 200 mg on days 2-3 + carboplatin AUC = 5 mg/ml/min (extensive-stage) or AUC = 6 mg/ml/min (limited-stage) on day 1 |
| Arnold et al.2007 | Vandetanib 300 mg/d daily | placebo 300 mg/d daily |
Abbreviations: ACT: angiogenesis inhibitors plus chemotherapy; CT: chemotherapy; AUC: area under the curve.